OTCM
TNBI
Market cap316kUSD
Jun 02, Last price
0.02USD
Name
Tanke Biosciences Corp
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Tanke Biosciences Corporation (TNBI) is a company dedicated to the development, production, and sale of a diverse portfolio of animal nutrition and feed additive products through its various subsidiaries. The company organizes its business into four distinct categories: organic trace mineral additives, functional regulation additives, herbal medicinal additives, and other related offerings. Among its product lineup, Tanke Biosciences provides organic trace mineral additives marketed under the Qili brand. It also produces Qilicid feed acidifiers, which are crucial for preventing microbial spoilage of raw ingredients and finished animal feeds. The company's offerings further include various seasonings and Tankeball branded flavor enhancers, designed to act as agents in the creation of blended feeds. For those seeking herbal solutions, Extra-Health, Qilimix, and Recoccider are names associated with its herbal medicinal additives, which are incorporated directly into feed products. Moreover, Tanke Biosciences manufactures and distributes a wide array of trace mineral premix products for livestock and poultry, also under the Qilimix label. Its Tankeball brand extends to natural sweeteners and attractants, specifically formulated for pigs, piglets, fish, and other aquatic animals. Another key product is a water-soluble organic multi-vitamin electrolyte, intended to be dissolved in drinking water for easy animal consumption. The company caters to a broad customer base, encompassing medium to large-scale feed production factories, major livestock operations, and individual farmers. Its products are primarily distributed and sold across the People's Republic of China, Southeast Asia, and Latin America. Tanke Biosciences Corporation was founded in 1989 and maintains its headquarters in Guangzhou, People's Republic of China.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | |||||||
Unusual Expense (Income) | |||||||
NOPBT | |||||||
NOPBT Margin | |||||||
Operating Taxes | |||||||
Tax Rate | |||||||
NOPAT | |||||||
Net income | |||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | |||||||
BB yield | |||||||
| Debt | |||||||
Debt current | |||||||
Long-term debt | |||||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | |||||||
| Cash flow | |||||||
Cash from operating activities | |||||||
CAPEX | |||||||
Cash from investing activities | |||||||
Cash from financing activities | |||||||
FCF | |||||||
| Balance | |||||||
Cash | |||||||
Long term investments | |||||||
Excess cash | |||||||
Stockholders' equity | |||||||
Invested Capital | |||||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | |||||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | |||||||
EV/EBITDA | |||||||
Interest | |||||||
Interest/NOPBT | |||||||